Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Narratives
Your Valuation
Community
/
Germany
/
Healthcare
Create a narrative
Fresenius SE KGaA Community
XTRA:FRE Community
2
Narratives
written by author
1
Comments
on narratives written by author
79
Fair Values set
on narratives written by author
Create a narrative
Fresenius SE KGaA
Popular
Undervalued
Overvalued
Community Investing Ideas
Fresenius SE KGaA
TO
Tokyo
Community Contributor
First comes the pain, then the money.
My main narrative for FRE: What former CEO Mark Schneider blow up to an inefficient giant, will now be cut down by actual CEO Michael Sen and trimmed on efficiency from formally 4 segments FMC (dialyses), Helios (private hospitals), Kabi(Generic & Infusions), Vamed (Projects & Digitalization) only 2 remain: Helios, Kabi, the other will be sold, and the intakes will help to restructure the financial situation under Mark Schneider the Spanish hospitals were acquired, this was a good deal: privat hospital runs well in Spain, because of their good reputation wealthy Latin Americans travel for medical treatments to Spain I focus also on: More equity than debt. Ratio is at 62% (debt/equity).
View narrative
€61.46
FV
32.0% undervalued
intrinsic discount
7.00%
Revenue growth p.a.
Set Fair Value
6
users have liked this narrative
0
users have commented on this narrative
15
users have followed this narrative
26 days ago
author updated this narrative
Fresenius SE KGaA
AN
AnalystConsensusTarget
Consensus Narrative from 15 Analysts
I Expect New Biopharma Products And The Ivenix Pump Will Streamline Future Operations
Key Takeaways Strategic focus on core businesses and asset divestment is set to enhance earnings and operational transparency. Innovations in Biopharma and MedTech will drive growth and improve margins, with new products boosting future revenue and stability.
View narrative
€46.99
FV
11.1% undervalued
intrinsic discount
4.57%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
24
users have followed this narrative
14 days ago
author updated this narrative
Your Valuation for
FRE
FRE
Fresenius SE KGaA
Your Fair Value
€
Current Price
€41.77
40.8% overvalued
intrinsic discount
Growth estimate over
Annual revenue growth rate
5 Years
time period
%/yr
Decrease
Increase
Past
Future
0
38b
2015
2018
2021
2024
2025
2027
2030
Revenue €27.8b
Earnings €1.5b
Advanced
Set Fair Value